Detalles de la búsqueda
1.
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Mol Cancer
; 22(1): 185, 2023 11 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37980528
2.
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Cancer Sci
; 114(12): 4622-4631, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37752769
3.
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
World J Urol
; 41(12): 3585-3591, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37924336
4.
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Clin Genitourin Cancer
; 22(1): 76-83, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880020
5.
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.
Clin Transl Radiat Oncol
; 39: 100558, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36545361
6.
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Cancer Med
; 12(19): 19414-19422, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37706578
7.
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Cancers (Basel)
; 14(22)2022 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36428750
Resultados
1 -
7
de 7
1
Próxima >
>>